跳至主要内容
临床试验/NCT04012242
NCT04012242Unknown不适用

Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study for Patients With Nonalcoholic Steatohepatitis

Tokyo Medical University18 个研究点 分布在 8 个国家目标入组 400 人开始时间: 2019年6月15日最近更新:
适应症

试验速览

阶段
不适用
入组人数
400
试验地点
18
主要终点
Diagnostic performance of Dispersion slope for intralobular inflammation (A01 vs. A23)

研究概览

简要总结

The objective of this study is: (1) to investigate the correlation of ultrasound parameters (SW speed, Dispersion slope, Attenuation value, Normalized Local Variance, Liver / Kidney Intensity Ratio) with the pathological parameters (fibrosis, intralobular inflammation, ballooning degeneration and steatosis); (2) to evaluate the diagnostic performance of SW speed for liver fibrosis, Dispersion slope for intralobular inflammation and Attenuation value for steatosis by comparison with the tissue diagnosis by liver biopsy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Nonalcoholic fatty liver disease (NAFLD) patients who are scheduled for liver biopsy for the differential diagnosis of NASH and/or NAFLD patients who are scheduled for the MR elastography (MRE) and MRI-proton density fat friction (MRI-PDFF).
  • Without a history of alcohol use, which lead to alcoholic hepatic involvement (pure alcohol below 30 g/day for male, 20 g/day for female).

排除标准

  • Patients with endocrine disorder (hypopituitarism, growth hormone deficiency, hyperthyroidism etc.), serious nutrition disorder, and drug-induced hepatic involvement (steroid, tamoxifen, valproic acid, amiodarone etc.), which may lead to the steatosis
  • Hepatitis B, Hepatitis C and HIV patients
  • Primary biliary cholangitis, Primary sclerosing cholangitis, and Autoimmune hepatitis patients
  • Wilson's disease, α1-antitrypsin deficiency, and hemochromatosis patients
  • Malignant liver tumor, common bile duct stone, and jaundice patients
  • Patients after jejunoileal bypass surgery or massive intestinal resection surgery
  • Patients whose treatment changes during the period between imaging examination and liver biopsy, including medications such as antidiabetic drugs and other treatments which may change the fat deposition or inflammation of liver.

结局指标

主要结局

Diagnostic performance of Dispersion slope for intralobular inflammation (A01 vs. A23)

时间窗: At the time of examination

次要结局

  • Correlation between ultrasound parameters and the pathological parameters(At the time of examination)
  • Diagnostic performance of the computer aided algorithm for NASH(At the time of examination)
  • Diagnostic performance of SW speed for fibrosis (F0 vs. F1234, F01 vs. F234, F012 vs. F34, and F0123 vs. F4).(At the time of examination)
  • Diagnostic performance of Normalized Local Variance for fibrosis (F0 vs. F1234, F01 vs. F234, F012 vs. F34, and F0123 vs. F4)(At the time of examination)
  • Diagnostic performance of Normalized Local Variance for steatosis (S0 vs. S123, S01 vs. S23, and S012 vs. S3)(At the time of examination)
  • Diagnostic performance of Dispersion slope for intralobular inflammation (A0 vs. A123, and A012 vs. A3)(At the time of examination)
  • Diagnostic performance of Attenuation value for steatosis (S0 vs. S123, S01 vs. S23, and S012 vs. S3)(At the time of examination)
  • Diagnostic performance of CAP for steatosis (S0 vs. S123, S01 vs. S23, and S012 vs. S3).(At the time of examination)
  • Diagnostic performance of MRE for fibrosis (F0 vs. F1234, F01 vs. F234, F012 vs. F34, and F0123 vs. F4).(At the time of examination)
  • Diagnostic performance of Liver/Kidney Intensity Ratio for steatosis (S0 vs. S123, S01 vs. S23, and S012 vs. S3)(At the time of examination)
  • Diagnostic performance of MRI-PDFF for steatosis (S0 vs. S123, S01 vs. S23, and S012 vs. S3).(At the time of examination)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Katsutoshi Sugimoto

Associate Professor

Tokyo Medical University

研究点 (18)

Loading locations...

相似试验

Innovative Liver Elasticity, Attenuation, and... | 临床试验